PL3481865T3 - Mutanty fc o ulepszonej aktywności funkcjonalnej - Google Patents

Mutanty fc o ulepszonej aktywności funkcjonalnej

Info

Publication number
PL3481865T3
PL3481865T3 PL17739229.7T PL17739229T PL3481865T3 PL 3481865 T3 PL3481865 T3 PL 3481865T3 PL 17739229 T PL17739229 T PL 17739229T PL 3481865 T3 PL3481865 T3 PL 3481865T3
Authority
PL
Poland
Prior art keywords
mutants
functional activity
improved functional
improved
activity
Prior art date
Application number
PL17739229.7T
Other languages
English (en)
Inventor
Céline MONNET
Original Assignee
Laboratoire Français Du Fractionnement Et Des Biotechnologies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoire Français Du Fractionnement Et Des Biotechnologies filed Critical Laboratoire Français Du Fractionnement Et Des Biotechnologies
Publication of PL3481865T3 publication Critical patent/PL3481865T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL17739229.7T 2016-07-06 2017-07-05 Mutanty fc o ulepszonej aktywności funkcjonalnej PL3481865T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1656463A FR3053688A1 (fr) 2016-07-06 2016-07-06 Mutants fc a activite fonctionnelle amelioree
PCT/EP2017/066791 WO2018007453A1 (fr) 2016-07-06 2017-07-05 Mutants fc a activite fonctionnelle amelioree

Publications (1)

Publication Number Publication Date
PL3481865T3 true PL3481865T3 (pl) 2024-02-19

Family

ID=57583168

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17739229.7T PL3481865T3 (pl) 2016-07-06 2017-07-05 Mutanty fc o ulepszonej aktywności funkcjonalnej

Country Status (8)

Country Link
US (1) US11814438B2 (pl)
EP (2) EP3481865B1 (pl)
CA (1) CA3029971A1 (pl)
DK (1) DK3481865T5 (pl)
ES (1) ES2965076T3 (pl)
FR (1) FR3053688A1 (pl)
PL (1) PL3481865T3 (pl)
WO (1) WO2018007453A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3075200B1 (fr) * 2017-12-15 2022-12-23 Lab Francais Du Fractionnement Variants avec fragment fc ayant une affinite augmentee pour fcrn et une affinite augmentee pour au moins un recepteur du fragment fc
WO2019235426A1 (ja) * 2018-06-04 2019-12-12 中外製薬株式会社 細胞質内での半減期が変化した抗原結合分子
EP4143224A1 (en) * 2020-05-01 2023-03-08 Novartis AG Immunoglobulin variants
AU2021275632A1 (en) * 2020-05-20 2023-02-02 Janssen Biotech, Inc. Site-specific conjugation of glycosylated monoclonal antibodies with transglutaminase
US12030945B2 (en) 2022-10-25 2024-07-09 Seismic Therapeutic, Inc. Variant IgG Fc polypeptides and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US7662925B2 (en) * 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US7317091B2 (en) * 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
EP2233500A1 (en) * 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
JP5972915B2 (ja) * 2011-03-16 2016-08-17 アムジエン・インコーポレーテツド Ｆｃ変異体
US11236168B2 (en) * 2012-08-24 2022-02-01 Chugai Seiyaku Kabushiki Kaisha Mouse FcγammaRII-specific Fc antibody
UY35148A (es) * 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
FR3003171B1 (fr) * 2013-03-15 2015-04-10 Lab Francais Du Fractionnement Nouveaux medicaments comprenant une composition d'anticorps enrichie en isoforme de charge majoritaire

Also Published As

Publication number Publication date
WO2018007453A1 (fr) 2018-01-11
EP3481865B1 (fr) 2023-09-06
CA3029971A1 (fr) 2018-01-11
FR3053688A1 (fr) 2018-01-12
ES2965076T3 (es) 2024-04-11
EP4273163A3 (fr) 2024-04-03
US20190309085A1 (en) 2019-10-10
EP3481865A1 (fr) 2019-05-15
US11814438B2 (en) 2023-11-14
DK3481865T5 (da) 2024-09-02
EP4273163A2 (fr) 2023-11-08
DK3481865T3 (da) 2023-12-11

Similar Documents

Publication Publication Date Title
ZA201704562B (en) Picolinamides with fungicidal activity
IL260128A (en) A system for creating a spray with electrodes
GB2557693C (en) Headgear assemblies and interface assemblies with headgear
EP3407941A4 (en) INJECTOR PEN ASSEMBLY
GB201406968D0 (en) Deletion mutants
PL3435804T3 (pl) Układ przyłbicy
IL249511B (en) Novel p450–bm3 variants with enhanced activity
PT3674004T (pt) Conjunto de bocal com face autolimpante
GB201616363D0 (en) Dust extractor with flat back
PL3481865T3 (pl) Mutanty fc o ulepszonej aktywności funkcjonalnej
AP2016009385A0 (en) Lancet assembly
IL256441B (en) New p450–bm3 variants with enhanced activity
PL3548758T3 (pl) Zespół ślizgowy
GB201622086D0 (en) Biocontrol organism
PT3430031T (pt) Péptidos com atividade anticancerígena
GB201420952D0 (en) Head unit with interchangeble functional bezel
GB201608056D0 (en) Improved analysis with preliminary survey
HUE047553T2 (hu) Dextrán-szaccharáz aktivitású protein és alkalmazásai
PL3303243T3 (pl) Lustro o ulepszonej trwałości
EP3279323A4 (en) Amadoriase having improved specific activity
ZA201705324B (en) Carbon activity analyser
GB2546297B (en) Retaining structure assembly
GB201520417D0 (en) Trenchcover with retainer
GB201509955D0 (en) Furniture etc covers etc
GB201416411D0 (en) Trenchcover with retainer